CYLD in health and disease.
José Luis Marín-RubioIshier RaoteJoseph InnsCarol Dobson-StoneNeil RajanPublished in: Disease models & mechanisms (2023)
CYLD lysine 63 deubiquitinase (CYLD) is a ubiquitin hydrolase with important roles in immunity and cancer. Complete CYLD ablation, truncation and expression of alternate isoforms, including short CYLD, drive distinct phenotypes and offer insights into CYLD function in inflammation, cell death, cell cycle progression and cell transformation. Research in diverse model systems has shown that these are mediated via CYLD regulation of cellular pathways including the NF-κB, Wnt and TGF-β pathways. Recent biochemical advances and models have offered new insights into the regulation and function of CYLD. In addition, recent discoveries of gain-of-function germline pathogenic CYLD variants in patients with a neurodegenerative phenotype contrast with the more widely known loss-of-function mutations seen in patients with CYLD cutaneous syndrome and with sporadic cancers. Here, we provide a current review of mechanistic insights into CYLD function gained from CYLD animal models, as well as an update on the role of CYLD in human disease.
Keyphrases
- cell cycle
- cell death
- cell proliferation
- public health
- oxidative stress
- stem cells
- signaling pathway
- magnetic resonance
- squamous cell carcinoma
- poor prognosis
- mental health
- single cell
- gene expression
- late onset
- binding protein
- epithelial mesenchymal transition
- toll like receptor
- dna repair
- transforming growth factor
- bone marrow
- amyotrophic lateral sclerosis
- genome wide
- cell cycle arrest